What Will Trump’s Second Term Mean for Pharma?
With Donald Trump back in the White House, biopharmaceutical companies face uncertainty around health policy and industry regulation. Issues in the spotlight include unconventional appointments to key positions, the roll-back of Biden-era drug pricing reforms and potential streamlining of approval processes. A radically different approach to healthcare would set the scene for major reform of principal agencies like the FDA and CMS. For dealmakers, initial hopes of a surge in M&A activity following Trump's victory have been tempered by the unpredictability of his economic and trade policies.
This Financial Times webinar showcased expert insights into shifts and shocks that could impact the pharma industry during President Trump’s second term, analyzing the risks and opportunities for investors and innovators in a potentially pivotal period for healthcare and life sciences.
Video on demand now available.
Key themes
How do investors feel about the life sciences dealmaking environment under Trump 2.0?
What are the prospects for a more business-friendly regulatory environment, especially around drug approvals?
How could industry and government work together to shape a mutually beneficial policy agenda?
Continue the discussion in-person
US Pharma and Biotech Summit
May 15th 2025 | In-Person & Online | New York
The Financial Times US Pharma and Biotech Summit will bring together top executives, investors and experts to share powerful insights into the future of life sciences in America and worldwide.
Not a subscriber of the FT?
When you purchase a ticket to one of our events you will receive a trial subscription for £1 giving you full digital access to essential news and opinion.
Upcoming Events from the Financial Times
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
